1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: Disease- specific recommendations

Clinical Infectious Diseases

Volumn 25, Issue SUPPL. 3, 1997, Pages

  Kaplan, Jonathan E ^a,b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIFUNGAL AGENT; ANTIMYCOBACTERIAL AGENT; ANTIPROTOZOAL AGENT; ANTIVIRUS AGENT; AZITHROMYCIN; BCG VACCINE; CIDOFOVIR; CLARITHROMYCIN; COTRIMOXAZOLE; DAPSONE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; FLUCONAZOLE; FOLINIC ACID; FOSCARNET; GANCICLOVIR; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; HERPES ZOSTER IMMUNOGLOBULIN; INFLUENZA VACCINE; ISONIAZID; ITRACONAZOLE; KETOCONAZOLE; MEASLES MUMPS RUBELLA VACCINE; PENTAMIDINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; PYRIMETHAMINE; TUBERCULOSTATIC AGENT; UNINDEXED DRUG;

CANDIDIASIS; COCCIDIOIDOMYCOSIS; CRYPTOCOCCOSIS; CRYPTOSPORIDIOSIS; CYTOMEGALOVIRUS INFECTION; HERPES SIMPLEX; HERPES ZOSTER; HISTOPLASMOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MYCOBACTERIOSIS; OPPORTUNISTIC INFECTION; ORAL DRUG ADMINISTRATION; PNEUMOCYSTIS PNEUMONIA; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; REVIEW; STREPTOCOCCUS INFECTION; TOXOPLASMOSIS; TUBERCULOSIS; VACCINATION;

EID: 0030838770     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/516252     Document Type: Review

References (13)

1. USPHS/IDSA Prevention of Opportunistic Infections Working Group. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1997:46(RR-12).
2. USPHS/IDSA Prevention of Opportunistic Infections Working Group. Preface to the 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Clin Infect Dis 1997;25:S299-312.
3. Kaplan JE, Masur H, Holmes KK, et al. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: an overview. Clin Infect Dis 1995;21(suppl 1):S12-S31.
4. El-Sadr W, Oleske JM, Agins BD, et al. Evaluation and management of early HIV infection. Clinical practice guideline no. 7. AHCPR publication no. 94-0572. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, 1994.
5. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society-USA Panel. JAMA 1997;277:1962-9.
6. Centers for Disease Control and Prevention. 1995 revised guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with or perinatally exposed to human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1995;44(RR-4).
7. Centers for Disease Control and Prevention. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Morb Mortal Wkly Rep 1994;43(RR-12).
8. American Academy of Pediatrics. 1997 Red Book: Report of the Committee on Infectious Diseases. 24th ed. Elk Grove Village, IL: American Academy of Pediatrics, 1997:294, 547.
9. Advisory Committee on Immunization Practices. Recommendations of the Advisory Committee on Immunization Practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence. MMWR Morb Mortal Wkly Rep 1993;42(RR-4).
10. Kurman RJ, Henson DE, Herbst AL, Noller RL, Schiffman MH. Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute workshop. JAMA 1994;271:1866-9.
11. Centers for Disease Control and Prevention. Clinical update: impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin. MMWR Morb Mortal Wkly Rep 1996;45:921-5.
12. Castro KG. Tuberculosis as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis 1995;21(suppl 1):S66-S71.
13. Ward JW, Hanson DL, Chu SY, Jones JJ. Survival and trends in anti-retroviral therapy and antimicrobial prophylaxis among persons with 1993-defined AIDS [abstract no. 1168]. In: Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1995:235.